Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(PF 04447943; PF04447943)
PF-04447943 Chemical Structure
|Product name: PF-04447943|
|Cat. No.: HY-15441|
PF-04447943 is a potent, selective brain penetrant PDE9 inhibitor (Ki of 2.8, 4.5 and 18 nM) for human, rhesus and rat recombinant PDE9 respectively and high selectivity for PDE9 versus PDEs1-8 and 10-11.
IC50 value: 2.8 nM (Human recombinant PDE9)
Target: PDE 9
PF-04447943 increased indicators of hippocampal synaptic plasticity and improved cognitive function in a variety of cognition models in both rats and mice. PF-04447943 was found to have high affinity (Ki of 2.8, 4.5 and 18 nM) for human, rhesus and rat recombinant PDE9 respectively and high selectivity for PDE9 versus PDEs1-8 and 10-11. Inhibition of phosphodiesterase 9 (PDE9) has been reported to enhance rodent cognitive function and may represent a potential novel approach to improving cognitive dysfunction in Alzheimer's disease.
|M.Wt||395.46||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
10 mM in DMSO
|1 mg||5 mg||10 mg|
|1 mM||2.5287 mL||12.6435 mL||25.2870 mL|
|5 mM||0.5057 mL||2.5287 mL||5.0574 mL|
|10 mM||0.2529 mL||1.2644 mL||2.5287 mL|
|Product Name||Sponsor Only||Condition||Start Date||End Date||Phase||Last Change Date|
|PF-04447943||Pfizer Inc||Alzheimers disease||30-SEP-09||30-SEP-10||Phase 2||22-APR-13|
|Pfizer Inc||Alzheimers disease||30-APR-10||01-JUL-10||Phase 1||14-SEP-13|
|Pfizer Inc||Alzheimers disease||31-OCT-09||31-JUL-10||Phase 1||13-SEP-13|
|Pfizer Inc||Cognitive disorder||31-AUG-09||01-NOV-09||Phase 1||14-SEP-13|
|Pfizer Inc||Cognitive disorder||31-JAN-09||01-MAY-09||Phase 1||14-SEP-13|
|Pfizer Inc||Cognitive disorder||30-APR-09||01-MAY-09||Phase 1||14-SEP-13|
. Hutson, P. H, et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology (2011), 61(4), 665-676.
. Claffey, Michelle M, et al. Application of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors. Journal of Medicinal Chemistry (2012), 55(21), 9055-9068.
. Verhoest, Patrick R, et al. Design and Discovery of 6-[(3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a Selective Brain Penetrant PDE9A Inhibitor for the Treatment of Cognitive Disorders. Journal of Medicinal Chemistry (2012), 55(21), 9045-9054.
Aminophylline is a competitive nonselective phosphodiesterase inhibitor that is used to treat airway obstruction from asthma or COPD.
AN-2728 is a topically administered, boron-containing, anti-inflammatory compound that inhibits PDE4 activity and thereby suppresses the release of TNFalpha, IL-12, IL-23 and other cytokines.
Anagrelide Hydrochloride(BL4162A) is a drug used for the treatment of essential thrombocytosis.
Apremilast(CC10004) is a novel small molecule inhibitor of PDE4 with an IC50 value of 74 nM.
Avanafil(TA-1790) is a potent and highly selective phosphodiesterase-5(PDE-5) inhibitor(IC50=5.2 nM) for erectile dysfunction; lower selectivity against PDE1, PDE6, and PDE11.
Bay 60-7550 is a potent PDE2 inhibitor with IC50 values of 2.0 nM (bovine) and 4.7 nM (human); 50-fold more selective for PDE2 compared to PDE1 and greater than 100-fold selective compared to PDE5, PDE3B, PDE4B, PDE7B, PDE8A, PDE9A, PDE10A, and PDE11A.
Cilomilast(SB 207499; Ariflo) is a potent PDE4 inhibitor with IC50 of about 110 nM, has anti-inflammatory activity and low central nervous system activity.
Cilostazol(OPC 13013; OPC 21) is a potent inhibitor of PDE3A, the isoform of PDE 3 in the cardiovascular system (IC50=0.2 uM).
Dyphylline acts as an adenosine receptor antagonist and phosphodiesterase inhibitor, which is used in the treatment of respiratory disorders.
Dipyridamole (Persantine) is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.